Moderna advances its investigational Bundibugyo ebolavirus vaccine toward a Phase 2/3 study

Observed price moves

• MRNA+1.30%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.